重組促紅血球生成素市場：依藥物類型、應用、通路和地區分類

Recombinant Erythropoietin Market, By Drug Type, By Application, By Distribution Channel, By Geography

出版日期: 2025年03月26日 | 出版商:

Coherent Market Insights | 英文 170 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

重組促紅血球生成素市場規模預計在 2025 年為 74.5 億美元，預計到 2032 年將達到 92.3 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 3.1%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	74.5億美元
效能數據	2020-2024	預測期	2025-2032
預測期：2025-2032年年複合成長率：	3.10%	2032年價值預測	92.3億美元

重組促紅血球生成素是促紅血球生成素的生物工程版本，促紅血球生成素是一種天然存在的激素，由腎臟產生，可刺激紅血球生成。這種重組促紅血球生成素通常在實驗室中使用基因改造細菌或哺乳動物細胞生產。重組促紅血球生成素主要用於治療貧血，尤其適用於慢性腎臟病病患者或接受癌症化療的患者。促紅血球生成素能刺激骨髓產生更多紅血球，進而提升血液的攜氧能力。

重組促紅血球生成素 (rEPO) 是一項突破性的醫學進展，徹底改變了貧血及相關疾病的治療方法。促紅血球生成素是一種由腎臟自然產生的激素，能夠刺激骨髓中紅血球 (RBC) 的生成。重組 DNA 技術使得在實驗室中合成促紅血球生成素成為可能，從而製造出了 rEPO。這為貧血管理提供了一種高效的方法，尤其適用於患有慢性腎臟病、癌症和某些遺傳性疾病的患者。透過使用 rEPO，醫護人員可以刺激紅血球生成，提高攜氧能力，並緩解貧血症狀，例如疲勞和虛弱。此外，rEPO 在減少輸血需求和改善患者生活品質方面已被證明具有顯著優勢。重組促紅血球生成素的廣泛應用徹底改變了貧血管理，並持續在各個醫療領域發揮關鍵作用。

市場動態：

預測期內，慢性腎臟病(CKD) 和癌症等慢性疾病的盛行率上升預計將推動全球重組促紅血球生成素市場的成長。例如，根據出版商 John Wiley & Sons, Inc. 於 2023 年 1 月 12 日發布的數據，預計 2023 年美國將新增 1,958,310 例癌症病例，並有 609,820 例癌症死亡病例。

然而，嚴格的監管要求、安全問題、副作用和報銷挑戰預計將在預測期內阻礙全球重組促紅血球生成素市場的成長。

本研究的主要特點

本報告對全球重組促紅血球生成素市場進行了詳細分析，並以 2024 年為基準年，展示了預測期（2025-2032 年）的市場規模和年複合成長率。
它還強調了各個領域的潛在商機，並解釋了該市場的有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
它根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，介紹了全球重組促紅血球生成素市場的主要企業概況。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興車型、市場擴張和行銷策略做出明智的決策。
本研究報告針對該產業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
相關人員將透過用於分析全球重組促紅血球生成素市場的各種策略矩陣來做出決策。

公司亮點
產品系列
主要進展
財務表現
策略
- 強生（楊森製藥）
公司亮點
產品系列
主要亮點
財務表現
策略
- 輝瑞公司
公司亮點
產品系列
主要亮點
財務表現
策略
- F.霍夫曼-羅氏公司
公司亮點
產品系列
主要亮點
財務表現
策略
- 諾華公司
公司亮點
產品系列
主要亮點
財務表現
策略
- 百奧康有限公司
公司亮點
產品系列
主要亮點
財務表現
策略
- LG化學有限公司
公司亮點
產品系列
主要亮點
財務表現
策略
- 英塔斯製藥股份有限公司
公司亮點
產品系列
主要亮點
財務表現
策略
- 雷迪博士實驗室公司
公司亮點
產品系列
主要亮點
財務表現
策略
- Celltrion公司
公司亮點
產品系列
主要亮點
財務表現
策略
- 三生製藥
公司亮點
產品系列
主要亮點
財務表現
策略
- 比奧西達斯公司
公司亮點
產品系列
主要亮點
財務表現
策略
- Astellas製藥公司
公司亮點
產品系列
主要亮點
財務表現
- 蓮花藥業有限公司
公司亮點
產品系列
主要亮點
財務表現
策略
分析師觀點

第 10 章章節

調查方法
關於出版商

簡介目錄

Product Code: CMI5960

Recombinant Erythropoietin Market is estimated to be valued at USD 7.45 Bn in 2025 and is expected to reach USD 9.23 Bn by 2032, growing at a compound annual growth rate (CAGR) of 3.1% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 7.45 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	3.10%	2032 Value Projection:	USD 9.23 Bn

Recombinant erythropoietin is a bioengineered version of a naturally occurring hormone, erythropoietin, which is produced by the kidneys to stimulate the production of red blood cells. This recombinant version is produced in a laboratory, typically using genetically modified bacteria or mammalian cells. Recombinant erythropoietin is used primarily to treat anemia, particularly in individuals with chronic kidney disease or undergoing chemotherapy for cancer. It works by stimulating the bone marrow to produce more red blood cells, thereby increasing the oxygen-carrying capacity of the blood.

Recombinant erythropoietin (rEPO) is a revolutionary medical development that has transformed the treatment of anemia and related conditions. Erythropoietin is a hormone naturally produced by the kidneys, stimulating the production of red blood cells (RBC) in the bone marrow. Recombinant DNA technology has made it possible to produce synthetic erythropoietin in the laboratory, resulting in the creation of rEPO. This has provided has provided a highly effective approach to managing anemia, particularly in patients with chronic kidney diseases, cancer, and certain genetic disorders. By administering rEPO, healthcare professionals can stimulate RBC production, improve oxygen-carrying capacity, and alleviating symptoms of anemia, such as fatigue and weakness. Furthermore, rEPO has demonstrated significant benefits in reducing the need for blood transfusions and enhancing quality of life for patients. The widespread adoption of recombinant erythropoietin has revolutionized anemia management and continues to play a crucial role in various medical fields.

Market Dynamics:

The rising prevalence of chronic diseases such as chronic kidney disease (ckd) and cancer is anticipated to drive growth of the global recombinant erythropoietin market over the forecast period. For instance, according to data published on January 12, 2023, by John Wiley & Sons, Inc., a publishing company, in 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the U.S.

However, stringent regulatory requirements, safety concerns, side effects, and reimbursement challenges are expected to hamper growth of the global recombinant erythropoietin market over the forecast period.

Key features of the study:

This report provides in-depth analysis of the global recombinant erythropoietin market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global recombinant erythropoietin market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Amgen Inc., Johnson & Johnson (Janssen Pharmaceuticals), Pfizer Inc., F. Hoffmann-La Roche AG, Novartis AG, Biocon Limited, LG Chem Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Celltrion Inc., 3SBio Inc., BioSidus SA, Astellas Pharma Inc, and Lotus Pharmaceutical Co., Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global recombinant erythropoietin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global recombinant erythropoietin market

Detailed Segmentation:

By Drug Type:
- Epoetin-alfa
- Epoetin-beta
- Darbepoetin-alfa
- Others
By Application:
- Cancer
- Hematology
- Renal diseases
- Neurology
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Amgen Inc.
- Johnson & Johnson (Janssen Pharmaceuticals)
- Pfizer Inc.
- F. Hoffmann-La Roche AG
- Novartis AG
- Biocon Limited
- LG Chem Ltd.
- Intas Pharmaceuticals Ltd.
- Dr. Reddy's Laboratories Ltd.
- Celltrion Inc.
- 3SBio Inc.
- BioSidus SA
- Astellas Pharma Inc
- Lotus Pharmaceutical Co., Ltd

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Recombinant Erythropoietin, By Drug Type
- Market Recombinant Erythropoietin, By Application
- Market Recombinant Erythropoietin, By Distribution Channel
- Market Recombinant Erythropoietin, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
Rising prevalence of chronic kidney disease (ckd)
- Restraints
Stringent Regulatory Requirements
- Opportunities
Emerging Markets
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Recombinant Erythropoietin Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Recombinant Erythropoietin Market , By Drug Type, 2020-2032, (US$ billion)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Epoetin-alfa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ billion)
Epoetin-beta
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ billion)
Darbepoetin-alfa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ billion)

6. Recombinant Erythropoietin Market, By Application, 2020-2032, (US$ billion)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ billion)
Hematology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ billion)
Renal diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ billion)
Neurology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ billion)

7. Recombinant Erythropoietin Market, By Distribution Channel, 2020-2032, (US$ billion)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ billion)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ billion)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ billion)

8. Recombinant Erythropoietin Market, By Region, 2020-2032, (US$ billion)

Introduction
- Market Share Analysis, By Country, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Country 2021-2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2020-2032,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ billion)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2020-2032,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ billion)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2020-2032,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ billion)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2020-2032,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ billion)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2020-2032,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ billion)
- 2020 - 2032, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2020-2032,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ billion)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2020 - 2032, (US$ Bn)
  - North Africa
  - Central Africa
  - South Africa